Takhzyro for hereditary angioedema in teenagers and adults
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study is for people in South Korea with hereditary angioedema. It looks at how well the drug Takhzyro works and how safe it is for teenagers and adults who are already using it or will start using it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older
- You have been diagnosed with hereditary angioedema
- You are taking Takhzyro or plan to take it as your doctor prescribed
- You or your guardian agree to take part in the study
- You are not currently in another experimental treatment trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Takhzyro (lanadelumab) works for people with a specific type of hereditary angioedema (HAE) that is caused by a C1 inhibitor deficiency. It is for teenagers and adults who have already been taking Takhzyro for at least 6 months.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This trial lets children who already took part in a previous CSL312 study for hereditary angioedema continue receiving the medicine. It helps ensure they don't have a gap in treatment while longer-term safety and effects are monitored.
This study tests a daily oral tablet called deucrictibant to see if it can prevent swelling attacks in people with hereditary angioedema (HAE). If you join, you will take the study drug for a longer period and track your symptoms in a diary.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study is looking at how hereditary angioedema (a rare cause of severe swelling) is diagnosed and managed in Egypt. It is an observational study, meaning you won't receive any study medicine—just regular medical care while researchers collect information.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.